Figures & data
Table 1 Details of drug concentration, dosing volume and final dose per animal
Table 2 Study design, study day 0 is the surgery day
Figure 1 Withdrawal force following treatment with Exparel, the liposomal formulation of bupivacaine (A) and Marcaine, a commercial bupivacaine solution (B) in the SMI model.
Abbreviation: SMI, skin and muscle incision.
![Figure 1 Withdrawal force following treatment with Exparel, the liposomal formulation of bupivacaine (A) and Marcaine, a commercial bupivacaine solution (B) in the SMI model.](/cms/asset/fdc082b2-d789-4bc1-8747-1737f8016888/djpr_a_144949_f0001_b.jpg)
Figure 2 Calculations of AUC expressing the level and duration of activity of the drugs.
Abbreviation: AUC, area under the curve.
![Figure 2 Calculations of AUC expressing the level and duration of activity of the drugs.](/cms/asset/b1dc88be-4c70-4e6a-8ccd-2bbc92354872/djpr_a_144949_f0002_b.jpg)
Table 3 The activity of local analgesics in SMI and SI incision models in pigs
Figure 3 Withdrawal force following treatment with Naropin (ropivacaine solution), Marcaine (bupivacaine solution) and Exparel (bupivacaine liposomal formulation) in an SI model in the pig.
Abbreviation: SI, skin incision.
![Figure 3 Withdrawal force following treatment with Naropin (ropivacaine solution), Marcaine (bupivacaine solution) and Exparel (bupivacaine liposomal formulation) in an SI model in the pig.](/cms/asset/e630d3fb-4e98-4fe8-9d28-60bc2832f304/djpr_a_144949_f0003_b.jpg)